Literature DB >> 28362208

The early-onset febrile reaction following vaccination and associated factors: An exploratory sub-study based on the Ebola vaccine clinical trial.

Qigang Dai1, Qi Liang1, Yuemei Hu1, Fanyue Meng1, Jingxin Li1, Lihua Hou2, Hailong Zhou3, Kai Chu1, Xiaokui Hu4, Rong Tang1, Wenjuan Wang1, Jialei Hu1, Haodi Huang1, Zhen Li1, Shuqi Yang1, Fengcai Zhu1.   

Abstract

A phase-1 clinical trial aimed to assess the safety and immunogenicity of the type-5 adenovirus vector based Ebola vaccine (Ad5-EBOV) was conducted in China. To provide more evidence for the safety evaluation and dose-selection, an exploratory sub-study using a wireless automatic temperature measuring platform was done based on the phase-1 clinical trial. The main aim of the sub-study was to obtain more information about the occurrence of fever and detect the potential associated factors, second was to assess the feasibility of the temperature measuring platform in vaccine clinical trials. Temperature data of 3 treatment groups all presented a rising tendency during the first 6 hours after vaccination, the incidence of elevated temperature and possible associated factors were analyzed. For the incidence of elevated temperature, no marked dose-response relationship was found in 6 hours with wireless thermometers; the information from mercury thermometers showed that the grade-1 fever proportion peaked at 6 hours and there was no difference between groups, while grade-2 fever proportion peaked at 24 hours and was significantly higher in high-dose group than those in the other 2 groups. Significant differences were found between sex groups (males vs. female, incidence rate ratios (IRR) = 2.93 and 7.62 for any-grade, grade-2 fever respectively, P<0.001); a decline in grade-2 fever incidence was found with the increasing age groups (IRR = 0.78, P = 0.003) and body mass index (BMI, IRR = 0.67, P<0.001) .Our findings show that the dose-dependent manner between fever and the dose of Ad5-EBOV in this study might emerge after 6 hours, and which is slight and transient. Wireless thermometers secured on the skin surface are not suitable for a long time (longer than 6 hours) measurement, new methods for temperature monitoring, like ear temperature measurement, should be tested in the further research.

Entities:  

Keywords:  Ebola vaccine; Febrile reaction; Wireless automatic temperature measuring platform; phase-1clinical trial

Mesh:

Substances:

Year:  2017        PMID: 28362208      PMCID: PMC5489280          DOI: 10.1080/21645515.2017.1288328

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  23 in total

Review 1.  Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation.

Authors:  S Michael Marcy; Katrin S Kohl; Ron Dagan; David Nalin; Michael Blum; Marcy Connell Jones; John Hansen; Jerry Labadie; Lucia Lee; Bryan L Martin; Katherine O'Brien; Edward Rothstein; Patricia Vermeer
Journal:  Vaccine       Date:  2004-01-26       Impact factor: 3.641

2.  Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial.

Authors:  Markus Pfister; Oliver Kürsteiner; Helene Hilfiker; Didier Favre; Peter Durrer; Abdallah Ennaji; Johanna L'Age-Stehr; Achim Kaufhold; Christian Herzog
Journal:  Am J Trop Med Hyg       Date:  2005-03       Impact factor: 2.345

3.  Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.

Authors:  A E Tozzi; A Anemona; P Stefanelli; S Salmaso; M L Ciofi degli Atti; P Mastrantonio; A Giammanco
Journal:  Pediatrics       Date:  2001-02       Impact factor: 7.124

4.  Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.

Authors:  Feng-Cai Zhu; Li-Hua Hou; Jing-Xin Li; Shi-Po Wu; Pei Liu; Gui-Rong Zhang; Yue-Mei Hu; Fan-Yue Meng; Jun-Jie Xu; Rong Tang; Jin-Long Zhang; Wen-Juan Wang; Lei Duan; Kai Chu; Qi Liang; Jia-Lei Hu; Li Luo; Tao Zhu; Jun-Zhi Wang; Wei Chen
Journal:  Lancet       Date:  2015-03-25       Impact factor: 79.321

5.  Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience.

Authors:  K M Neuzil; W D Dupont; P F Wright; K M Edwards
Journal:  Pediatr Infect Dis J       Date:  2001-08       Impact factor: 2.129

6.  Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA 27/3 rubella immunisation.

Authors:  A J Tingle; M Allen; R E Petty; G D Kettyls; J K Chantler
Journal:  Ann Rheum Dis       Date:  1986-02       Impact factor: 19.103

7.  Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial.

Authors:  T M Govaert; G J Dinant; K Aretz; N Masurel; M J Sprenger; J A Knottnerus
Journal:  BMJ       Date:  1993-10-16

Review 8.  The Xs and Y of immune responses to viral vaccines.

Authors:  Sabra L Klein; Anne Jedlicka; Andrew Pekosz
Journal:  Lancet Infect Dis       Date:  2010-05       Impact factor: 71.421

9.  Smart multi-level tool for remote patient monitoring based on a wireless sensor network and mobile augmented reality.

Authors:  Fernando Cornelio Jiménez González; Osslan Osiris Vergara Villegas; Dulce Esperanza Torres Ramírez; Vianey Guadalupe Cruz Sánchez; Humberto Ochoa Domínguez
Journal:  Sensors (Basel)       Date:  2014-09-16       Impact factor: 3.576

10.  Body height affects the strength of immune response in young men, but not young women.

Authors:  Indrikis A Krams; Ilona Skrinda; Sanita Kecko; Fhionna R Moore; Tatjana Krama; Ants Kaasik; Laila Meija; Vilnis Lietuvietis; Markus J Rantala
Journal:  Sci Rep       Date:  2014-08-28       Impact factor: 4.379

View more
  2 in total

Review 1.  Sex Differences in Immunity: Implications for the Development of Novel Vaccines Against Emerging Pathogens.

Authors:  Anahita Fathi; Marylyn M Addo; Christine Dahlke
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

2.  Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer.

Authors:  D Sangiolo; G Valabrega; S Capellero; J Erriquez; C Melano; G Mesiano; S Genta; A Pisacane; G Mittica; E Ghisoni; M Olivero; M F Di Renzo; M Aglietta
Journal:  Sci Rep       Date:  2020-04-15       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.